Metformin Exosomes Show Promise in Lab MS Cells
Adults with relapsing-remitting multiple sclerosis may one day benefit, but these early findings come from cells studied outside the body.
Updated on Nov. 4, 2026 in Stroke

Researchers tested metformin-loaded exosomes derived from human fat-tissue stem cells on immune cells taken from patients with relapsing-remitting multiple sclerosis, in laboratory conditions. The combined treatment reduced inflammatory immune cell populations and boosted regulatory cells within days, offering a preliminary signal for a delivery approach to the drug.
Why it matters
Metformin is widely used for diabetes, but its rapid clearance and poor bioavailability have limited its translation into treatment for relapsing-remitting multiple sclerosis. Using mesenchymal stem cell exosomes as a delivery system aims to improve drug stability, a strategy that could matter for people living with this immune-driven disease if it proves workable in patients.
This is an in vitro study using blood cells from patients and healthy controls, with cell frequencies measured by flow cytometry at 24 and 72 hours. Because the work was conducted outside the body, the findings are preliminary and do not show effects in people with multiple sclerosis.
The details
Exosomes are tiny vesicles released by cells that can carry molecules between cells; here, human fat-derived stem cell exosomes were loaded with metformin to act as a protective carrier. In the lab, the metformin-loaded exosomes (Exo-Met) reduced IL-17-producing and IFN-γ-producing CD4+ T cells, which drive inflammation, while enriching FoxP3+ CD25+ regulatory T cells that help restrain the immune response. Metformin alone and exosomes alone each produced partial effects, but the combination acted faster on IL-17 and more strongly on IFN-γ, pointing to a possible advantage from the delivery system.
Timeline
Cell frequencies were measured at 24 hours and 72 hours after treatment in the laboratory experiments reported in the study, published November 4, 2026.
Health Landscape
Current relapsing-remitting multiple sclerosis treatments target immune activity, and researchers are exploring ways to improve how existing drugs reach the immune system. Exosome-based delivery is an emerging area of research, and this laboratory work adds metformin to the list of candidate drugs being tested with that approach.
If you have relapsing-remitting multiple sclerosis, this study does not change current care, and any interest in experimental approaches is worth raising with your neurologist. Because the findings come from laboratory cells rather than people, there is no practical change to make now.
The takeaway
Early laboratory work suggests that stem cell exosomes could help a common diabetes drug reach the immune system more effectively in multiple sclerosis. Anyone interested in emerging therapies should ask their neurologist which research is relevant to their specific situation.
Further reading
For broader context on how neurological conditions are studied and treated, explore the Stroke section.
Source note: This article includes information reported by Nature.


